Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
Gridelli C, Curcio C, Iaffaioli RV, Brancaccio L, D'Aprile M, Gebbia V, Rossi A, Tortoriello A, Veltri E, Maione P, Barbarisi A, Gallo C, Guida C, Perrone F. Gridelli C, et al. Among authors: barbarisi a. Anticancer Res. 2001 Nov-Dec;21(6A):4179-83. Anticancer Res. 2001. PMID: 11911315 Clinical Trial.
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV, Tortoriello A, Santangelo M, Turitto G, Libutti M, Benassai G, Frattolillo A, Ciccarelli PD, De Rosa P, Crovella F, Carbone I, Barbarisi A. Iaffaioli RV, et al. Among authors: barbarisi a. Clin Oncol (R Coll Radiol). 2000;12(4):251-5. doi: 10.1053/clon.2000.9167. Clin Oncol (R Coll Radiol). 2000. PMID: 11005695 Clinical Trial.
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Iaffaioli RV, Tortoriello A, Gravina A, Facchini G, Turitto G, Elia S, Griffo S, Gentile M, Fraioli G, Frattolillo A, Muto P, Libutti M, De Marino V, Illiano A, Barbarisi A. Iaffaioli RV, et al. Among authors: barbarisi a. Lung Cancer. 2000 Dec;30(3):203-10. doi: 10.1016/s0169-5002(00)00144-6. Lung Cancer. 2000. PMID: 11137206 Clinical Trial.
Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.
Barbarisi M, Barbarisi A, De Sena G, Armenia E, Aurilio C, Libutti M, Iaffaioli RV, Botti G, Maurea N, Quagliariello V. Barbarisi M, et al. Among authors: barbarisi a. Phytother Res. 2019 Jun;33(6):1670-1682. doi: 10.1002/ptr.6354. Epub 2019 Mar 28. Phytother Res. 2019. PMID: 30924205
Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting.
Quagliariello V, Gennari A, Jain SA, Rosso F, Iaffaioli RV, Barbarisi A, Barbarisi M, Tirelli N. Quagliariello V, et al. Among authors: barbarisi a. Mater Sci Eng C Mater Biol Appl. 2021 Dec;131:112475. doi: 10.1016/j.msec.2021.112475. Epub 2021 Oct 12. Mater Sci Eng C Mater Biol Appl. 2021. PMID: 34857264 Free article.
Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer.
Quagliariello V, Iaffaioli RV, Armenia E, Clemente O, Barbarisi M, Nasti G, Berretta M, Ottaiano A, Barbarisi A. Quagliariello V, et al. Among authors: barbarisi m, barbarisi a. J Cell Physiol. 2017 Aug;232(8):2063-2074. doi: 10.1002/jcp.25587. Epub 2017 Mar 1. J Cell Physiol. 2017. PMID: 27607841
Pain in Intensive Care: A Narrative Review.
Pota V, Coppolino F, Barbarisi A, Passavanti MB, Aurilio C, Sansone P, Pace MC. Pota V, et al. Among authors: barbarisi a. Pain Ther. 2022 Jun;11(2):359-367. doi: 10.1007/s40122-022-00366-0. Epub 2022 Feb 27. Pain Ther. 2022. PMID: 35220551 Free PMC article. Review.
75 results